TEVA Pharmaceutical (NYSE: TEVA) Form 144 lists 17,295 shares for resale

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited submitted a Form 144 reporting the sale of 17,295 ordinary shares under Rule 144. The filing references a Restricted Share Unit award vesting dated 03/05/2025 and lists 03/05/2026 and the NYSE in the securities table.

Insights

Securities Compliance Analyst

Form 144 lists a Rule 144 resale of 17,295 ordinary shares tied to an RSU vesting.

The entry shows 17,295 ordinary shares associated with a Restricted Share Unit award vesting on 03/05/2025. The table also references 03/05/2026 and the NYSE.

Filing details such as the seller identity, exact proceeds treatment, and the specific sale methods are not included in the excerpt; subsequent filings or broker disclosures would report execution specifics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:49 PM Learn about SEC filing dates

FAQ

What does TEVA's Form 144 report?

The Form 144 reports the resale of 17,295 ordinary shares under Rule 144. It ties the shares to a Restricted Share Unit award vesting dated 03/05/2025 and lists the NYSE in the securities table.

Does the filing state when the RSUs vested for TEVA?

Yes. The excerpt references a Restricted Share Unit award vesting with a date of 03/05/2025. The Form 144 entry links that vesting to the 17,295 ordinary shares noted in the filing.

How many TEVA shares are listed for resale in the excerpt?

The excerpt lists 17,295 ordinary shares as the securities noted in the Form 144 entry. No aggregate proceeds or seller identity are clearly labeled in the provided text.

Does the Form 144 excerpt show where TEVA shares will trade?

The securities table includes the exchange label NYSE, indicating the class is listed there. The excerpt does not specify execution methods or timing for any resale transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	17295	547704.98	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			17295	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)